Elevated plasma lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease (CVD). Although Lp(a) consists of an apolipoprotein(a) molecule bound to an ApoB-containing LDL-like particle, most conventional lipid-lowering agents have minimal effects on Lp(a) level.
Lp(a) levels are predominantly regulated by apo(a) biosynthesis, which is almost entirely determined by hepatic transcription of the APOA gene, rather than clearance or circulating concentrations of its other components.
2 ApoB-lowering therapies, such as mipomersen, lower Lp(a) by 21%-33% presumably by reducing ApoB available for Lp(a) assembly.
3 PCSK9 inhibition produces strongly correlated reductions in both Lp(a) (−32%) and ApoB (−56%). 4 These and our data suggest that Lp(a) reductions following RYGB are not primarily ApoB dependent.
We hypothesize that the RYGB-specific reductions in Lp(a) are related to differences in postsurgical anatomy and physiology between the 2 procedures that affect bile acid levels, and are distinct from mechanisms of existing therapies. RYGB creates a Roux limb that bypasses the duodenum, which may explain increased circulating bile acids after RYGB. 5 SG reduces stomach volume without bypassing gastrointestinal anatomy. The few small studies of the effect of SG on circulating bile acids in humans have demonstrated modest (relative to RYGB) and inconsistent results across varied durations of follow-up. 5 Some data point to an early postoperative increase in bile acids following SG, which is transient. Although the causes underlying a transient increase are uncertain, this observation supports our hypothesized mechanism related to bile acids to explain the differing changes in Lp(a) following SG and RYGB in this study given that circulating bile acids suppress apo(a) transcription in mice via negative regulation by Farnesoid X receptor (FXR), a bile acid-activated nuclear receptor. This is complemented by human data showing that FXR agonist use in cholestatic patients reduced Lp(a). 6 We acknowledge that our study is limited by a homogeneous population that may limit generalizability. Additionally, a minority of our subjects exhibited pathologically high Lp(a) preoperatively. Nonetheless, the degree of reduction in Lp(a) was comparable between RYGB subjects with Lp(a) greater and less than 30 mg/dL. In summary, in the first prospective comparison of Lp(a) and ApoB in the 2 most common bariatric procedures, we demonstrate procedure-dependent effects on Lp(a). Future translational studies measuring bile acids and Lp(a) in humans undergoing bariatric surgery and direct tissue FXR and apo(a) expression assessments in animal models will begin to definitively elucidate the mechanism underlying RYGB-specific reductions in Lp(a) and may provide insight into novel therapies for this CVD risk factor.
